6-KThe Wire
Telix Pharmaceuticals Ltd files 6-K
Filed Apr 10, 2026 · 2mo ago · Accession 0001628280-26-024572
Plain English
The FDA has accepted Telix Pharmaceuticals' resubmitted New Drug Application (NDA) for TLX101-Px (Pixclara), an investigational PET agent for imaging glioma, with a PDUFA goal date of September 11, 2026. Telix's FY 2026 financial guidance does not include any revenue contribution from TLX101-Px.
Filing details
- Company
- Telix Pharmaceuticals Ltd
- Ticker
- TLX
- CIK
- 2007191
- Form type
- 6-K
- Filing date
- Apr 10, 2026
- Report date
- Apr 9, 2026
- Document
- a20260410pixclarandaacce.htm
- Size
- 976 KB
More from TLX
6-KThe WireJul 2, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSMay 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 23, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 20, 20266-KThe WireApr 14, 2026